Anderson S, Mauskopf J, Talbird SE, White A, Meenakshi S. Antiseizure medications and oral contraceptives: impact of enzyme inducers on pregnancy outcomes and costs. Epilepsy Behav. 2021 Dec;125:108368. doi: 10.1016/j.yebeh.2021.108368
Rockwood NJ, Jeon M. Estimating complex measurement and growth models using the R package PLmixed. Multivar Behav Res. 2019 Mar;54(2):288-306. doi: 10.1080/00273171.2018.1516541
Ibañez A, Aguado J, Baez S, Huepe D, Lopez V, Ortega R, Sigman M, Mikulan E, Lischinsky L, Torrente F, Cetkovich M, Torralva T, Bekinschtein T, Manes F. From neural signatures of emotional modulation to social cognition: individual differences in healthy volunteers and psychiatric participants. Soc Cogn Affect Neur. 2014 Jul;9(7):939-50.
Ettinger AB, Manjunath R, Candrilli SD, Davis KL. Prevalence and cost of nonadherence with antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav. 2009 Feb;14(2):324-9. doi: 10.1016/j.yebeh.2008.10.021.
Manjunath RY, Davis KL, Candrilli SD, Ettinger AE. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav. 2009 Jan;14(2):372-8.
Offen W, Chuang-Stein C, Dmitrienko A, Copley-Merriman K. Multiple co-primary endpoints: medical and statistical solutions: a report from the multiple endpoints expert team of the PhRMA. Drug Inf J. 2007;4:31-46.
Backhouse ME, Gnanasakthy A, Schulman KA, Akehurst R, Glick H. The development of standard economic datasets for use in the economic evaluation of medicines. Drug Inf J. 2000;34(4):1273-91.
Ciociola AA, Webb DD, McSorley DJ. The continued use of placebo-controlled clinical trials in the study of peptic ulcer disease: a sponsor perspective. Drug Inf J. 1996 Apr;30(2):433-9.
Doward LC. Developing a measure of quality of life for patients with recurrent genital herpes. Drug Inf J. 1994 Jan 1;28(1):19-25.
Koch GG, Amara LA, Forster JK, McSorley DJ, Peace KE. Statistical issues in the design and analysis of ulcer healing and recurrence studies. Drug Inf J. 1993 Jul;27(3):805-24.